logo
Plus   Neg
Share
Email

Genentech: Tecentriq, Avastin Combination Study Meets Co-primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said Tecentriq in combination with Avastin, as a treatment for people with unresectable hepatocellular carcinoma who have not received prior systemic therapy, showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with standard-of-care sorafenib in a Phase III IMbrave150 study. Safety data for the combination was consistent with the safety profiles of the individual medicines.

In July 2018, the U.S. FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in hepatocellular carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Panera Bread Co. is launching a new subscription program that will allow customers to drink unlimited coffee and tea. The new program of $8.99 per month launches Thursday and covers hot coffee, iced coffee and hot tea. With the introduction of the subscription, Panera becomes the first national restaurant company to offer unlimited hot drip coffee, iced coffee and hot tea for $8.99 per month. Best Buy Co. Inc. (BBY) Thursday reported a fourth-quarter profit that increased 1.4 percent from last year, while, J. C. Penney Co.'s (JCP) quarterly profit dropped 64 percent. However, the results of the companies topped analysts' estimates. Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall.
Follow RTT
>